These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1864 related articles for article (PubMed ID: 17517853)

  • 1. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    Nissen SE; Wolski K
    N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
    Nissen SE; Wolski K
    Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
    Boyle P
    South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
    [No Abstract]   [Full Text] [Related]  

  • 4. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
    Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Avandia debacle: methodology and practical importance of the findings.
    Meneghini LF; Florez H; Tamariz L
    South Med J; 2007 Nov; 100(11):1062-3. PubMed ID: 17984727
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
    McGuire DK
    Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosiglitazone and cardiovascular risk.
    Diamond GA; Kaul S
    N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
    [No Abstract]   [Full Text] [Related]  

  • 14. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
    Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
    BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone and cardiovascular risk.
    Bracken MB
    N Engl J Med; 2007 Aug; 357(9):937-8; author reply 939-40. PubMed ID: 17761600
    [No Abstract]   [Full Text] [Related]  

  • 16. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Oct; 82(1):48-57. PubMed ID: 18775581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone: a thunderstorm from scarce and fragile data.
    Mulrow CD; Cornell J; Localio AR
    Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
    [No Abstract]   [Full Text] [Related]  

  • 18. The record on rosiglitazone and the risk of myocardial infarction.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.